- Subjects with diagnosed acromegaly who were already being treated with Somavert® or
were to start treatment with Somavert® were included in the study.
- Subjects treated with an investigational drug for treatment of acromegaly.
- Subjects with symptoms such visual field loss, cranial nerve palsies or intracranial
hypertension, indicating need for surgery.
- Women who were pregnant or lactating.